CStone Pharmaceuticals Unveils CS2015, a Breakthrough Bispecific Antibody at ACAAI 2025 CStone Pharmaceuticals presents CS2015, a bispecific antibody, at the ACAAI 2025. This innovative therapy targets key inflammation pathways, showing promise for autoimmune conditions.

CStone Pharmaceuticals Unveils CS2015, a Breakthrough Bispecific Antibody at ACAAI 2025 #China #Suzhou #CStone_Pharmaceuticals #CS2015 #ACAAI